Pharsight

Fintepla generic

Fintepla is a drug owned by Zogenix Inc. that contains the active ingredient fenfluramine hydrochloride. It first hit the market on 25 June, 2020. The drug is available in solution;oral dosage forms and has a total of 24 patents.

When will Fintepla generic be available?

The generic version of Fintepla could be available after the expiry of the last patent on 29 December, 2038.

Fintepla uses

Fintepla is primarily used for the treatment of refractory epilepsy patients with fenfluramine, which reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution. The drug is also used in combination with other drugs such as cannabidiol, stiripentol, valproate, and clobazam for the treatment of seizures associated with Dravet syndrome and Lennox Gastaut syndrome.

Fintepla patent expiration

Fintepla, with the active ingredient Fenfluramine Hydrochloride, is protected by 24 patents. The patents cover aspects from methods of treatment to formulation techniques. The most recent patent protecting Fintepla generic will expire on 29 December, 2038. Below are the details of the patent:

EPO Oppostions filed on Fintepla

Fintepla dosage

Want to ask something?